focus -WSS

focus

author：leisure time 2025-10-02 20:15:24 Page View：6564

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： I was wrong about Geron's blood cancer drug. Now, is it a takeover target?
Next article： Alkermes shareholders re

explore

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

AstraZeneca to buy developer of next

AlastairGrant/APLONDON—AstraZenecasaidTuesdayitwouldacquireFusionPharmaceuticalsinadealworthmorethan

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Leading voice in opioid treatment defends methadone clinic system

MarkParrino:"Idon’tthinkthedominantinterestisjustgivinglotsmoretake-homestopatients.There’smoretotre

focus

Wikipedia

explore

Leading voice in opioid treatment defends methadone clinic system